Ferric carboxymaltose (FCM) is a nondextran IV iron formulation designed for rapid, high-dose iron replacement therapy. Its structure allows for the slow release of bioavailable iron, substantially reducing the risk of free iron toxicity. In clinical practice, FCM is typically administered at doses of 500–1000 mg per infusion, with the maximum single dose often capped at 1000 mg and repeated if needed to correct the calculated iron deficit – often determined by the Ganzoni formula as done in the present study.[1] The possibility to deliver large doses (up to 1000 mg over 15 min) distinguishes FCM from earlier-generation iron preparations, which require more frequent and lower-dose administrations.[2]
Clinical Uses
The approved indications for ferric carboxymaltose include:
Iron deficiency anemia in adults where oral iron is ineffective or not tolerated
Chronic kidney disease patients, especially those on hemodialysis
Perioperative management of anemia in elective surgeries
Gynecology and obstetrics: Pregnant women experiencing iron deficiency anemia, especially in later trimesters or with intolerance to oral iron
Gastrointestinal conditions: Such as inflammatory bowel disease, where chronic blood loss and malabsorption are common.[3]
FCM’s rapid and effective correction of iron stores makes it particularly useful for individuals with symptomatic anemia requiring swift recovery, and in populations with high rates of oral iron intolerance, as highlighted in the studied cohort.[4]
Recent Advances
Recent years have brought several noteworthy developments in FCM’s clinical application:
Expanded dosing regimens
Some studies explore higher cumulative doses and flexible serial dosing for those with severe deficits.
New indications
Emerging evidence supports FCM’s use beyond anemia, such as in symptomatic heart failure with iron deficiency, which improves symptoms and quality of life.
Comparative effectiveness
Head-to-head trials with iron sucrose and other IV iron products demonstrate faster and greater increases in hemoglobin and iron indices with FCM, with fewer dosing sessions required.
Pediatrics and perioperative care
Recent trials have tested FCM in pediatric anemia and surgical settings, with promising results but an ongoing need for further safety data.
Limitations and Knowledge Gaps
Despite the robust results in both this trial and others, IV FCM therapy is not without limitations:
Cost
Relative to oral iron and some older IV formulations, FCM is expensive, limiting access in low-resource settings, such as the rural and tribal areas studied.[2]
Requirement for infrastructure
IV infusions need medical supervision, venous access, and monitoring for hypersensitivity reactions, posing challenges in outreach clinics and remote regions.[1,2]
Outcomes beyond laboratory parameters
While hematologic correction is well-demonstrated, longer-term outcomes such as maternal/neonatal morbidity, quality of life, or functional improvement require more study.[3]
Subgroup evidence
Data for specific populations (tribal, children, and certain chronic diseases) remain limited, and additional research is needed to confirm generalizability.[4]
Adherence and follow-up
The present study had a short follow-up and did not assess long-term recurrence rates or iron repletion maintenance.[5]
Adverse Effects
FCM is generally well tolerated, with a markedly reduced risk of serious hypersensitivity reactions thanks to its nondextran, carbohydrate shell.
Common or reported adverse effects include:
Mild symptoms
Nausea, headache, dizziness, and injection site reactions (pain and erythema).
Transient hypophosphatemia: Several studies describe reductions in serum phosphate, usually asymptomatic but occasionally severe or prolonged, especially following repeat high doses[5]
Allergic reactions: Although rare, anaphylactoid reactions can occur and require appropriate monitoring during and after infusion[6]
Other: Rare reports of skin staining (extravasation), hypertension during infusion, and musculoskeletal pain.[7]
In the provided study, no significant adverse effects were observed, attesting to FCM’s favourable safety profile when IV administration protocols are followed. However, real-world data suggest ongoing vigilance is necessary, especially given underreporting in resource-limited settings or studies with small sample sizes.
Conflicts of interest
There are no conflicts of interest.
Funding Statement
Nil.
References
- 1.Rathod S, Samal SK, Mahapatra PC, Samal S. Ferric carboxymaltose: A revolution in the treatment of postpartum anemia in Indian women. Int J Appl Basic Med Res. 2015;5:25–30. doi: 10.4103/2229-516X.149230. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Qunibi WY. The efficacy and safety of intravenous iron preparations: Focus on ferric carboxymaltose and iron isomaltoside. Kidney Int Suppl. 2020;10:2–7. [Google Scholar]
- 3.Khanna U, Perugu PK, Kumar A, Sheth S, Gaikwad A, Gajbe P, et al. AIM HD-CKD study: Assessment of the efficacy and safety of ferric carboxymaltose in iron deficiency anemia management in haemodialysis patients with chronic kidney disease. Int J Clin Trials. 2025;12:80–6. [Google Scholar]
- 4.Girelli D, Marchi G, Camaschella C. ‘An update on iron metabolism and iron disorders. Haematologica. 2021;106:2160–73. [Google Scholar]
- 5.Anker SD, Comin-Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in iron-deficient heart failure. N Engl J Med. 2009;361:2436–48. doi: 10.1056/NEJMoa0908355. [DOI] [PubMed] [Google Scholar]
- 6.Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013;28:1793–803. doi: 10.1002/jbmr.1923. [DOI] [PubMed] [Google Scholar]
- 7.Onken JE, Bregman DB, Harrington RA, Morris D, Buerkert J, Hamerski D, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: The REPAIR-IDA trial. Nephrol Dial Transplant. 2014;29:833–42. doi: 10.1093/ndt/gft251. [DOI] [PubMed] [Google Scholar]